Mumbai: Pharma major Lupin Limited today announced the appointment of Yashwant Mahadik as President – Global Human Resources (HR). He will lead the HR function for Lupin globally.
Yash is a seasoned HR professional with nearly three decades of experience across diverse sectors such as consumer and healthcare in global organizations. His last assignment was with Sun Pharmaceuticals as Global Chief Human Resources Officer prior to which he held HR roles with increasing responsibilities at companies like Philips, Johnson & Johnson, AstraZeneca and Colgate Palmolive.
Yash brings to Lupin rich experience in HR and business transformation across global markets. He has an MBA in General Management and International Human Resource Management from University of Sheffield, United Kingdom, and is a Certified Associate Executive Coach from Franklin Covey and Results Coaching System, USA. Yash is a renowned thought leader in HR and has collaborated with leading global academicians to conceptualize and execute strategic initiatives in the field of Human Resource Management.
Commenting on the appointment, Nilesh Gupta – Managing Director, Lupin Limited said, “Lupin has a tremendous track record of growth over the past decade which has established a solid foundation as a global pharmaceutical major. This is a critical time for the Pharmaceutical Industry and we are delighted to have Yash join Lupin as we transition our business to a Specialty pharmaceutical and Complex Generics major globally. Our strong HR practices and employee experience have led Lupin to be consistently recognized as one of the best companies to work for. We are confident that Yash will continue to build on our strong HR foundation and help us create a world-class organization.”
Yash will be based in Mumbai, India and will report to Vinita Gupta – Chief Executive Officer, Lupin and Nilesh Gupta – Managing Director, Lupin.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 12th and 8th largest generics pharmaceutical company by market capitalization (31st March 2018, Bloomberg) and revenues (31st Mar 2018, Bloomberg LTM) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT March 2018); 3rd largest Indian pharmaceutical company by global revenues (31st Mar 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT March 2018).
For the financial year ended 31st March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries, please contact –
VP – Corporate Communications
Ph: +91-22-66402531 / 8291013225
Head – Investor Relations